Yoshida Takuo, Uchino Shigehiko, Sasabuchi Yusuke, Kyo Michihito, Igarashi Takashi, Inoue Haruka
Intensive Care Unit, Department of Anesthesiology, Jikei University School of Medicine, Tokyo, Japan.
Data Science Center, Jichi Medical University, Tochigi, Japan.
Int J Cardiol Heart Vasc. 2021 Mar 1;33:100742. doi: 10.1016/j.ijcha.2021.100742. eCollection 2021 Apr.
Sustained new-onset atrial fibrillation (AF) in the intensive care unit has been reported to be associated with poor outcomes. However, in critical illness, whether rhythm-control therapy can achieve sinus rhythm (SR) restoration is unknown. This study aimed to assess the impact of rhythm-control therapy on SR restoration for new-onset AF in critically ill patients.
This post-hoc analysis of a prospective multicenter observational study involving 32 Japan intensive care units compared patients with and without rhythm-control therapy for new-onset atrial fibrillation (AF) and conducted a multivariable analysis using Cox proportional hazards regression analysis including rhythm-control therapy as a time-varying covariate for SR restoration.
Of 423 new-onset AF patients, 178 patients (42%) underwent rhythm-control therapy. Among those patients, 131 (31%) underwent rhythm-control therapy within 6 h after AF onset. Magnesium sulphate was the most frequently used rhythm-control drug. The Cox proportional hazards model for SR restoration showed that rhythm-control therapy had a significant positive association with SR restoration (adjusted hazard ratio: 1.46; 95% confidence interval: 1.16-1.85). However, the rhythm-control group had numerically higher hospital mortality than the non-rhythm-control group (31% vs. 23%, p = 0.09).
Rhythm-control therapy for new-onset AF in critically ill patients was associated with SR restoration. However, patients with rhythm-control therapy had poorer prognosis, possibly due to selection bias. These findings may provide important insight for the design and feasibility of interventional studies assessing rhythm-control therapy in new-onset AF.
据报道,重症监护病房中持续新发房颤(AF)与不良预后相关。然而,在危重病中,节律控制疗法能否实现窦性心律(SR)恢复尚不清楚。本研究旨在评估节律控制疗法对危重病患者新发房颤恢复窦性心律的影响。
这项对涉及32个日本重症监护病房的前瞻性多中心观察性研究的事后分析,比较了接受和未接受新发房颤节律控制疗法的患者,并使用Cox比例风险回归分析进行多变量分析,将节律控制疗法作为恢复窦性心律的时变协变量。
在423例新发房颤患者中,178例(42%)接受了节律控制疗法。在这些患者中,131例(31%)在房颤发作后6小时内接受了节律控制疗法。硫酸镁是最常用的节律控制药物。恢复窦性心律的Cox比例风险模型显示,节律控制疗法与恢复窦性心律有显著正相关(调整后风险比:1.46;95%置信区间:1.16-1.85)。然而,节律控制组的医院死亡率在数值上高于非节律控制组(31%对23%,p = 0.09)。
危重病患者新发房颤的节律控制疗法与恢复窦性心律相关。然而,接受节律控制疗法的患者预后较差,可能是由于选择偏倚。这些发现可能为评估新发房颤节律控制疗法的干预性研究的设计和可行性提供重要见解。